Zimmer Biomet (NYSE:ZBH) today touted data highlighting the clinical value of its MyMobility platform with Apple Watch.
Warsaw, Indiana-based Zimmer Biomet announced four data presentations on MyMobility with Apple Watch, which it touts as a first-of-its-kind remote care management platform for helping healthcare professionals remotely support and guide patients during their preparation for and recovery from orthopedic procedures.
Data on MyMobility with Apple Watch, which constitutes part of the company’s ZBEdge suite of connected digital and robotic technologies, was presented at the American Academy of Orthopaedic Surgeons (AAOS) 2021 annual meeting.
Zimmer Biomet’s data included a study of 337 patients who underwent primary total knee arthroplasty that determined the impact on postoperative outcomes with the use of a self-directed rehabilitation program administered through MyMobility with education and video-directed exercise programs paired with an Apple Watch to help track the patient’s physical activity.
Researchers concluded that a postoperative SDR program administered through a mobile application paired with a smartwatch can provide similar patient-reported outcome measures while not affecting manipulation rates or compromising range of motion, regardless of the level of compliance with the application exercise program, according to a news release.
“The introduction of mymobility with Apple Watch underscores Zimmer Biomet’s commitment to evaluating the real-world clinical benefits of a remote care management platform after orthopedic surgery,” Zimmer Biomet VP & GM of connected health Robert Kraal said in the release. “These four analyses, utilizing interim data from the ongoing mymobility Clinical Study, suggest that MyMobility with Apple Watch may be a viable option to help healthcare professionals monitor how a patient is progressing after surgery and remotely manage rehabilitation regimens to optimize recovery.”
